Home Equities Score Lipocine Inc. (LPCN) stock fell during pre-market trading. Here’s to know why?

Lipocine Inc. (LPCN) stock fell during pre-market trading. Here’s to know why?

Lipocine Inc. (NASDAQ: LPCN) stock declined by 1.55% at last close whereas the LPCN stock price plunged by 2.36% in the pre-market trading session. Lipocine is a clinical-stage biopharmaceutical business that uses its patented drug delivery technology to treat metabolic and endocrine diseases.

>> 7 Top Picks for the Post-Pandemic Economy << 

What is happening?

Clarus and Lipocine reached a settlement for all remaining claims in Lipocine’s patent infringement litigation against Clarus, as well as a patent interference dispute between the two companies. Lipocine filed a patent infringement lawsuit against Clarus in response to Clarus’s marketing of JATENZO, an oral testosterone replacement therapy. A Clarus patent application was awaiting issue by the USPTO at the time of the interference action.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Clarus’ motion for summary judgment of invalidity of all of Lipocine’s alleged patent claims in the action was granted on May 25, 2021. Lipocine and Clarus have decided to terminate the Lipocine Inc. v. Clarus Therapeutics, Inc., Civil Action No. 19-cv-622 lawsuit now ongoing in the United States District Court for the District of Delaware, as part of the settlement reported today. Moreover, both parties have entered into an agreement on the interference, which is now pending at the USPTO and is titled Clarus Therapeutics, Inc. v. Lipocine Inc., Interference No. 106,128. The specifics of the settlement aren’t public, but they don’t include any money from Clarus to Lipocine.

Read More

Past Development

Lipocine has reported that the U.S. The Food and Drug Administration has given LPCN approval to begin a Phase 2 trial to assess the therapeutic effects of LPCN 1154, an oral neuro-steroid product candidate, for the therapy of postpartum depression in adults.

In July 2021, a pharmacokinetic study to determine dosage proportionality will begin, with top-line results anticipated in the third quarter of 2021. A proof-of-concept trial to investigate the safety, acceptability, and effectiveness of LPCN 1154 in adult female patients diagnosed with PPD is planned to begin in the fourth quarter of 2021, after the PK study.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Onesmart International Education Group Ltd. (ONE) stock surges during current market. What’s driving it high?

Onesmart International Education Group Ltd. (NASDAQ: ONE) stock gains by 111.86% in the current market trading session. OneSmart International Education is a major Chinese...

LivePerson Inc. (LPSN) stock plunge during pre-market. What’s driving it low?

LivePerson Inc. (NASDAQ: LPSN) stock gained by 0.86% at last close whereas the LPSN stock declines by 9.39% in the pre-market trading session. Through...

The Clorox Company Ltd. (CLX) stock decline during pre-market. Here’s the recent update

The Clorox Company Ltd. (NASDAQ: CLX) stock gained by 0.17% at last close whereas the CLX stock price fell by 11.59% in the pre-market....

IT Tech Packaging Inc. (ITP) stock gains during pre-market. Here’s what’s happening?

IT Tech Packaging Inc. (NASDAQ: ITP) stock gained by 7.53% at last close while the ITP stock price rises by 2.04% in the pre-market...

Why did The9 Limited (NCTY) stock turnaround in the after-hours on Friday?

The9 Limited (NCTY) shares gained 6.87% in after-hours on Friday, July 30, 2021, and closed the weekly trading at $11.98 per share. in the...

NANO; The future of payment?

In 2008 an unidentified individual named Satoshi Nakamoto came forward with the first white paper for a concept of a decentralized currency market with...

Trevena Inc. (TRVN) stock surges during after-market, given no current update

Trevena Inc. (NASDAQ: TRVN) stock declined by 8.09% at last close whereas the TRVN stock-price gains by 8.8% in the after-hours trading. Trevena, Inc....

Nevro Corp Inc. (NVRO) stock plunge during after-market. Here’s to know why?

Nevro Corp Inc. (NASDAQ: NVRO) stock declined by 2.19% at last close while the NVRO stock price plunge by 18.86% in the after-market. Nevro...

Related News

Trevena Inc. (TRVN) stock surges during after-market, given no current update

Trevena Inc. (NASDAQ: TRVN) stock declined by 8.09% at last close whereas the TRVN stock-price gains by 8.8% in the after-hours trading. Trevena, Inc....

Nevro Corp Inc. (NVRO) stock plunge during after-market. Here’s to know why?

Nevro Corp Inc. (NASDAQ: NVRO) stock declined by 2.19% at last close while the NVRO stock price plunge by 18.86% in the after-market. Nevro...

OneConnect Financial Technology Inc. (OCFT) stock plunge during current market. Here’s what you should know.

OneConnect Financial Technology Inc. (NASDAQ: OCFT) stock declines by 22.12% in the current market trading. In China, OneConnect is the most popular technology-as-a-service platform...

Invitae Corporation Inc. (NVTA) stock surge during current market. Here’s the update:

Invitae Corporation Inc. (NASDAQ: NVTA) stock gains by 12.35% in the current market trading session. Invitae Corporation is a prominent medical genetics business whose...

Alto Ingredients Inc. (ALTO) stock fall during pre-market trading. Here’s what you should know?

Alto Ingredients Inc. (NASDAQ: ALTO) stock gained by 5.99% at last close whereas the ALTO stock-price plunge by 9.89% in the pre-market trading session....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam